The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease
Open accessAbstract
OBJECTIVE: A workgroup commissioned by the Alzheimer's Association (AA) and the National Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease (AD). We performed a preliminary assessment of these guidelines. METHODS: We employed Pittsburgh compound B positron emission tomography (PET) imaging as our biomarker of cerebral amyloidosis, and (18) fluorodeoxyglucose PET imaging and hippocampal volume as biomarkers of neurodegeneration. A group of 42 clinically diagnosed AD subjects was used to create imaging biomarker cutpoints. A group of 450 cognitively normal (CN) subjects from a population-based sample was used to develop cognitive cutpoints and to assess population frequencies of the different preclinical AD stages using different cutpoint criteria. RESULTS: The new criteria subdivide the preclinical phase of AD into stages 1 to 3. To classify our CN subjects, 2 additional categories were needed. Stage 0 denotes subjects with normal AD biomarkers and no evidence of subtle cognitive impairment. Suspected non-AD pathophysiology (SNAP) denotes subjects with normal amyloid PET imaging, but abnormal neurodegeneration biomarker studies. At fixed cutpoints corresponding to 90% sensitivity for diagnosing AD and the 10th percentile of CN cognitive scores, 43% of our sample was classified as stage 0, 16% stage 1, 12 % stage 2, 3% stage 3, and 23% SNAP. INTERPRETATION: This cross-sectional evaluation of the NIA-AA criteria for preclinical AD indicates that the 1-3 staging criteria coupled with stage 0 and SNAP categories classify 97% of CN subjects from a population-based sample, leaving only 3% unclassified. Future longitudinal validation of the criteria will be important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial studies in this emerging area have identified subgroups of older adults with subtle cognitive decline that do not conform to expected patterns and investigators have designated them as Suspected Non-Alzheimer Pathology (SNAP) and Unclassified groups [51, 52].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [51]
Experimental — accuracy not yet measuredIn the citing paper
“Our hypothesis, therefore, can accommodate a growing realization that for many subjects with suspected AD, or who have an increased risk of developing AD, what are currently considered downstream biomarker changes potentially precede upstream biomarker changes [206-213].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [212]
In the citing paper
“Yet, this finding is in line with recent studies showing that AD-type atrophy and/or hypometabolism can be found in both Aβ-negative healthy controls (Jack et al., 2012) and Aβ-negative MCI patients (Prestia et al., 2013).”
From Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia (2013) · cites this paper as Jack et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Cited by
Sorted by citations
Items 201–300 of 601
Shen, X., Li, J., Wang, H., Li, H., Huang, Y., Yang, Y., Tan, L., Dong, Q., Yu, J., & Initiative, A. D. N. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12104 · Cited by 57
Altered Executive Function in Pre-Mild Cognitive Impairment
Seo, E. H., Kim, H., Lee, K. H., & Choo, I. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160052 · Cited by 58
Valech, N., Tort‐Merino, A., Coll‐Padrós, N., Olives, J., León, M., Rami, L., & Molinuevo, J. L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170627 · Cited by 61
Lazarczyk, M. J., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-127 · Cited by 55
Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
Dumurgier, J., Mouton‐Liger, F., Lapalus, P., Prévot, M., Laplanche, J., Hugon, J., Paquet, C., & for the Groupe d’Investigation du Liquide Cephalorachidien (GIL) Study Network (2013) · PLoS ONE · doi:10.1371/journal.pone.0053587 · Cited by 55
Scarpa, M., Hesse, S., & Bradley, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.003 · Cited by 55
Schreiber, S., Drukarch, B., Garz, C., Niklass, S., Stanaszek, L., Kropf, S., Bueche, C. Z., Held, F., Vielhaber, S., Attems, J., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132618 · Cited by 55
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Panza, F., Solfrizzi, V., Imbimbo, B. P., Giannini, M., Santamato, A., Seripa, D., & Logroscino, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945522 · Cited by 51
Epidemiological Approaches to Understanding the Link Between Type 2 Diabetes and Dementia
Sutherland, G. T., Lim, J., Srikanth, V. K., & Bruce, D. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161194 · Cited by 58
Imaging Alzheimer's disease pathophysiology with PET
Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., Borelli, W. V., Palmini, A., Gauthier, S. G., & Rosa‐Neto, P. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1002003 · Cited by 57
Cued memory decline in biomarker-defined preclinical Alzheimer disease
Papp, K. V., Rentz, D. M., Mormino, E. C., Schultz, A. P., Amariglio, R. E., Quiroz, Y., Johnson, K. A., & Sperling, R. A. (2017) · Neurology · doi:10.1212/wnl.0000000000003812 · Cited by 52
Rethinking on the concept of biomarkers in preclinical Alzheimer’s disease
Berti, V., Polito, C., Lombardi, G., Ferrari, C., Sorbi, S., & Pupi, A. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2477-1 · Cited by 54
Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI
Lowe, V. J., Peller, P. J., Weigand, S. D., Quintero, C. M., Tosakulwong, N., Vemuri, P., Senjem, M. L., Jordan, L. G., Jack, C. R., Knopman, D. S., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d6cf · Cited by 50
Self-citationMcDonough, I. M., Bischof, G. N., Kennedy, K. M., Rodrigue, K. M., Farrell, M. E., & Park, D. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.011 · Cited by 51
Emerging biomarkers and screening for cognitive frailty
Ruan, Q., D’Onofrio, G., Sancarlo, D., Greco, A., Lozupone, M., Seripa, D., Panza, F., & Yu, Z. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-017-0741-8 · Cited by 53
Suspected non-Alzheimer's pathology – Is it non-Alzheimer's or non-amyloid?
Dani, M., Brooks, D. J., & Edison, P. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.003 · Cited by 50
Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer’s Disease
Pereira, J. B., van Westen, D., Stomrud, E., Strandberg, T. O., Volpe, G., Westman, E., & Hansson, O. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx236 · Cited by 48
Arendash, G. W., Cao, C., Abulaban, H., Baranowski, R., Wisniewski, G., Becerra, L. R., Andel, R., Lin, X., Zhang, X., Wittwer, D., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190367 · Cited by 52
Abnormal tau in amyloid PET negative individuals
Yoon, B., Guo, T., Provost, K., Korman, D., Ward, T. J., Landau, S. M., & Jagust, W. J. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.019 · Cited by 52
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 55
Hickman, R. A., Flowers, X. E., & Wısnıewskı, T. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01063-1 · Cited by 48
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project
Initiative, F. T. A. D. N., van Maurik, I. S., Slot, R. E. R., Verfaillie, S. C. J., Zwan, M. D., Bouwman, F. H., Prins, N. D., Teunissen, C. E., Scheltens, P., Barkhof, F., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0487-y · Cited by 47
Memory, executive, and multidomain subtle cognitive impairment
Toledo, J. B., Bjerke, M., Chen, K., Rozycki, M., Jack, C. R., Weiner, M. W., Arnold, S. E., Reiman, E. M., Davatzikos, C. A., Shaw, L. M. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001738 · Cited by 48
Self-citationCerin, E., Rainey‐Smith, S. R., Ames, D. J., Lautenschlager, N. T., Macaulay, S. L., Fowler, C. J., Robertson, J. S., Rowe, C. C., Maruff, P. T., Martins, R. N., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.2364 · Cited by 49
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 47
A practical guideline for intracranial volume estimation in patients with Alzheimer's disease
Sargolzaei, S., Sargolzaei, A., Cabrerizo, M., Chen, G., Goryawala, M., Noei, S., Zhou, Q., Duara, R., Barker, W., & Adjouadi, M. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s7-s8 · Cited by 46
Yener, G., Emek‐Savaş, D. D., Lizio, R., Çavuşoğlu, B., Carducci, F., Ada, E., Güntekin, B., Babiloni, C., & Başar, E. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.02.005 · Cited by 48
Advances in amyloid beta oligomer detection applications in Alzheimer's disease
Jamerlan, A., An, S. S. A., & Hulme, J. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.115919 · Cited by 46
Sex influences the effects of APOE genotype and Alzheimer’s diagnosis on neuropathology and memory
Duarte‐Guterman, P., Albert, A., Barha, C. K., Galea, L. A. M., & Initiative, O. B. O. T. A. D. N. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105248 · Cited by 48
Ossenkoppele, R., Madison, C. M., Oh, H., Wirth, M., van Berckel, B. N. M., & Jagust, W. J. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht076 · Cited by 45
Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife
Racine, A. M., Koscik, R. L., Berman, S. E., Nicholas, C. R. N., Clark, L. R., Okonkwo, O. C., Rowley, H. A., Asthana, S., Bendlin, B. B., Blennow, K., et al. (2016) · Brain · doi:10.1093/brain/aww142 · Cited by 46
Krell‐Roesch, J., Ruider, H., Lowe, V. J., Stokin, G. B., Pink, A., Roberts, R. O., Mielke, M. M., Knopman, D. S., Christianson, T. J. H., Machulda, M. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160326 · Cited by 48
Self-citationEnrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration
Wolz, R., Schwarz, A. J., Gray, K. R., Yu, P., Hill, D., & Initiative, A. D. N. (2016) · Neurology · doi:10.1212/wnl.0000000000003126 · Cited by 46
Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging
Wennberg, A. M. V., Lesnick, T. G., Schwarz, C. G., Savica, R., Hagen, C. E., Roberts, R. O., Knopman, D. S., Hollman, J. H., Vemuri, P., Jack, C. R., et al. (2017) · The Journals of Gerontology Series A · doi:10.1093/gerona/glx240 · Cited by 45
Self-citationMormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44
Multimorbidity and neuroimaging biomarkers among cognitively normal persons
Vassilaki, M. E., Aakre, J. A., Mielke, M. M., Geda, Y. E., Kremers, W. K., Alhurani, R. E., Machulda, M. M., Knopman, D. S., Petersen, R. C., Lowe, V. J., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002624 · Cited by 45
Self-citationStricker, N. H., Lundt, E. S., Albertson, S. M., Machulda, M. M., Pudumjee, S. B., Kremers, W. K., Jack, C. R., Knopman, D. S., Petersen, R. C., & Mielke, M. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200087 · Cited by 44
Self-citationYu, P., Sun, J., Wolz, R., Stephenson, D. T., Brewer, J. B., Fox, N. C., Cole, P. E., Jack, C. R., Hill, D., & Schwarz, A. J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.039 · Cited by 45
Self-citationCortical thickness mediates the effect of β-amyloid on episodic memory
Villeneuve, S., Reed, B., Wirth, M., Haase, C. M., Madison, C., Ayakta, N., Mack, W., Mungas, D., Chui, H., Decarli, C., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000170 · Cited by 43
Herman Buschke, L., Mowrey, W. B., Ramratan, W. S., Zimmerman, M. E., Loewenstein, D., Katz, M. J., & Lipton, R. B. (2016) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acw083 · Cited by 48
Burnham, S. C., Coloma, P. M., Li, Q.-X., Collins, S. J., Savage, G. R., Laws, S. M., Doecke, J. D., Maruff, P. T., Martins, R. N., Ames, D. J., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.25 · Cited by 43
Meyer, P., Savard, M., Poirier, J., Labonté, A., Rosa‐Neto, P., Weitz, T. M., Town, T., Breitner, J. C. S., & Initiative, A. D. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170887 · Cited by 44
A machine learning approach to screen for preclinical Alzheimer's disease
Gaubert, S., Houot, M., Raimondo, F., Ansart, M., Corsi, M., Naccache, L., Sitt, J. D., Habert, M., Dubois, B., Fallani, F. D. V., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.024 · Cited by 43
Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions
Wisse, L. E. M., Ravikumar, S., Ittyerah, R., Lim, S., Lane, J., Bedard, M. L., Xie, L., Das, S. R., Schuck, T., Grossman, M., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01225-3 · Cited by 43
Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline
Lan, G., Cai, Y. Q., Li, A., Liu, Z., Ma, S., Guo, T., & Initiative, A. D. N. (2022) · Annals of Neurology · doi:10.1002/ana.26492 · Cited by 42
Panza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41
Estimating Intracranial Volume in Brain Research: An Evaluation of Methods
Sargolzaei, S., Sargolzaei, A., Cabrerizo, M., Chen, G., Goryawala, M., Pinzon-Ardila, A., Gonzalez‐Arias, S., & Adjouadi, M. (2015) · Neuroinformatics · doi:10.1007/s12021-015-9266-5 · Cited by 42
Howe, A. S. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.10.019 · Cited by 41
Clinical Diagnosis of Alzheimer’s Disease
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00002-x · Cited by 46
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
Altomare, D., Caprioglio, C., Assal, F., Allali, G., Mendes, A., Ribaldi, F., Ceyzériat, K., Martins, M., Tomczyk, S., Stampacchia, S., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05246-x · Cited by 40
Tarawneh, H. Y., Mulders, W. H. A. M., Sohrabi, H. R., Martins, R. N., & Jayakody, D. M. P. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210556 · Cited by 40
Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry
Graff‐Radford, J., Lesnick, T. G., Boeve, B. F., Przybelski, S. A., Jones, D. T., Senjem, M. L., Gunter, J. L., Ferman, T. J., Knopman, D. S., Murray, M. E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26666 · Cited by 39
Self-citationMagnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease
Knight, M. J., McCann, B., Kauppinen, R. A., & Coulthard, E. J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00139 · Cited by 41
Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease
Pettigrew, C. A., Soldan, A., Sloane, K. L., Cai, Q., Wang, J., Wang, M., Moghekar, A., Miller, M. I., & Albert, M. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.08.022 · Cited by 39
Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force
Gauthier, S. G., Alam, J., Fillit, H. M., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M. N., Salloway, S., Sampaio, C., Sims, J. R., Sperling, B. K., et al. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.12 · Cited by 39
Ataxin-2 gene: a powerful modulator of neurological disorders
Laffita‐Mesa, J. M., Paucar, M., & Svenningsson, P. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000959 · Cited by 44
Lee, R., Kim, J.-H., Kim, W., Hwang, S., Choi, S.-H., Kim, J., Cho, I., Kim, M., & Nah, S.-Y. (2024) · Journal of Ginseng Research · doi:10.1016/j.jgr.2024.02.002 · Cited by 43
A robust biomarker of large‐scale network failure in Alzheimer's disease
Wiepert, D. A., Lowe, V. J., Knopman, D. S., Boeve, B. F., Graff‐Radford, J., Petersen, R. C., Jack, C. R., & Jones, D. T. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.004 · Cited by 38
Self-citationWirth, M., Bejanin, A., Joie, R. L., Arenaza‐Urquijo, E. M., Gonneaud, J., Landeau, B., Perrotin, A., Mézenge, F., Sayette, V. D. L., Desgranges, B., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.023 · Cited by 40
Schwarz, A. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01027-4 · Cited by 40
Mecca, A. P., Barcelos, N. M., Wang, S., Brück, A., Nabulsi, N., Planeta‐Wilson, B., Nadelmann, J. B., Benincasa, A. L., Ropchan, J. R., Huang, Y. H., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.027 · Cited by 40
Mielke, M. M., Weigand, S. D., Wiste, H. J., Vemuri, P., Machulda, M. M., Knopman, D. S., Lowe, V. J., Roberts, R. O., Kantarci, K., Rocca, W. A., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.09.001 · Cited by 41
Self-citationPeter, J., Kaiser, J., Landerer, V., Schumacher, L. V., Kaller, C. P., Heimbach, B., Hüll, M., Bormann, T., & Klöppel, S. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.09.024 · Cited by 36
Tardif, C. L., Devenyi, G. A., Amaral, R. S. C., Pelleïeux, S., Poirier, J., Rosa‐Neto, P., Breitner, J. C. S., & Chakravarty, M. M. (2017) · Human Brain Mapping · doi:10.1002/hbm.23897 · Cited by 36
Role of FABP3 as Biomarker in Alzheimer's Disease and Synucleinopathies
Sepe, F. N., Chiasserini, D., & Parnetti, L. (2018) · Future Neurology · doi:10.2217/fnl-2018-0003 · Cited by 38
Allegri, R., Méndez, P. C., Calandri, I. L., Cohen, G., Martín, M., Russo, M. J., Crivelli, L., Pertierra, L., Tapajóz, F., Clarens, M. F., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12026 · Cited by 36
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
Insel, P. S., Mattsson, N., Mackin, R. S., Kornak, J., Nosheny, R. L., Tosun, D., Donohue, M., Aisen, P. S. S., Weiner, M. W., & Initiative, A. D. N. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.192 · Cited by 34
Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment
Louwersheimer, E., Wolfsgruber, S., Espinosa, A., Lacour, A., Heilmann‐Heimbach, S., Alegret, M., Hernández, I., Rosende‐Roca, M., Tárraga, L., Boada, M., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.006 · Cited by 35
Zhao, Y., Tudorascu, D., López, O. L., Cohen, A. D., Mathis, C. A., Aizenstein, H. J., Price, J. C., Kuller, L. H., Kamboh, M. I., DeKosky, S. T., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3029 · Cited by 35
Allison, S. L., Rodebaugh, T. L., Johnston, C., Fagan, A. M., Morris, J. C., & Head, D. M. (2019) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acz019 · Cited by 35
Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology
Wisse, L. E. M., de Florès, R., Xie, L., Das, S. R., McMillan, C. T., Trojanowski, J. Q., Grossman, M., Lee, E. B., Irwin, D. J., Yushkevich, P. A., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00835-2 · Cited by 37
Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research
Bieger, A., Brum, W. S., Borelli, W. V., Therriault, J., Bastiani, M. A. D., Moreira, A. G., Benedet, A. L., Ferrari‐Souza, J. P., da Costa, J. C., Souza, D. O., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209753 · Cited by 35
A biomarker study in long-lasting amnestic mild cognitive impairment
Cerami, C., Dodich, A., Iannaccone, S., Magnani, G., Santangelo, R., Presotto, L., Marcone, A., Gianolli, L., Cappa, S. F., & Perani, D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0369-8 · Cited by 37
Schreiber, S., Schreiber, F., Lockhart, S. N., Horng, A., Bejanin, A., Landau, S. M., Jagust, W. J., & Initiative, A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5349 · Cited by 33
Veličkaitė, V., Ferreira, D., Cavallin, L., Lind, L., Ahlström, H. K., Kilander, L., Westman, E., & Larsson, E. (2017) · European Radiology · doi:10.1007/s00330-017-5103-6 · Cited by 38
Peter, J., Sandkamp, R., Minkova, L., Schumacher, L. V., Kaller, C. P., Abdulkadir, A., & Klöppel, S. (2017) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.12.014 · Cited by 34
Fletcher, E. M., Villeneuve, S., Maillard, P., Harvey, D. J., Reed, B., Jagust, W. J., & DeCarli, C. S. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.133 · Cited by 35
Cognitive Domain Dispersion Association with Alzheimer’s Disease Pathology
Malek‐Ahmadi, M. H., Lu, S., Chan, Y., Perez, S. E., Chen, K., & Mufson, E. J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161233 · Cited by 34
Odor identification ability predicts PET amyloid status and memory decline in older adults
Kreisl, W., Jin, P., Lee, S., Dayan, E., Vallabhajosula, S., Pelton, G., Luchsinger, J., Pradhaban, G., & Devanand, D. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170960 · Cited by 32
AD risk score for the early phases of disease based on unsupervised machine learning
Wang, Z., Tang, Z., Zhu, Y., Pettigrew, C. A., Soldan, A., Gross, A. L., & Albert, M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12140 · Cited by 34
Lan, G., Li, A., Liu, Z., Ma, S., Guo, T., & Initiative, A. D. N. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12890 · Cited by 31
Mhatre, S. D., Michelson, S. J., Gomes, J., Tabb, L. P., Saunders, A. J., & Marenda, D. R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.08.021 · Cited by 34
Mar, J., Soto‐Gordoa, M., Arrospide, A., Moreno, F., & Martínez‐Lage, P. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0079-9 · Cited by 31
Multimorbidity Is Associated with Preclinical Alzheimer’s Disease Neuroimaging Biomarkers
Mendes, A., du Montcel, S. T., Lévy, M., Bertrand, A., Habert, M., Bertin, H., Dubois, B., Epelbaum, S., & INSIGHT-PreAD study group (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000489007 · Cited by 33
McRae‐McKee, K., Evans, S., Hadjichrysanthou, C., Wong, M. M., de Wolf, F., & Anderson, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42632-w · Cited by 32
Tsai, C., Pai, M., Ukropec, J., & Ukropcová, B. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151093 · Cited by 32
Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment
Peter, J., Lahr, J., Minkova, L., Lauer, E. M., Grothe, M. J., Teipel, S. J., Köstering, L., Kaller, C. P., Heimbach, B., Hüll, M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160273 · Cited by 30
Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline
Hohman, T. J., Tommet, D., Marks, S. M., Contreras, J. A., Jones, R. N., & Mungas, D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.022 · Cited by 33
Nemes, S., Logan, P. E., Manchella, M. K., Mundada, N. S., Joie, R. L., Polsinelli, A. J., Hammers, D. B., Koeppe, R. A., Foroud, T., Nudelman, K. N. H., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13403 · Cited by 32
Self-citationAge and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002979 · Cited by 30
Self-citationZhang, B., Ferman, T. J., Boeve, B. F., Smith, G. E., Maroney‐Smith, M., Spychalla, A. J., Knopman, D. S., Jack, C. R., Petersen, R. C., & Kantarci, K. (2014) · Journal of Neuroimaging · doi:10.1111/jon.12138 · Cited by 29
Self-citationNeuropathologic features of TOMM40 '523 variant on late‐life cognitive decline
Yu, L., Lutz, M. W., Farfel, J. M., Wilson, R. S., Burns, D. K., Saunders, A. M., Jager, P. L. D., Barnes, L. L., Schneider, J. A., & Bennett, D. A. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.05.002 · Cited by 29
Wu, K., Lin, K., Chen, C., Chen, C., Liu, C., Huang, S., Yen, T., & Hsiao, I. (2018) · Brain and Behavior · doi:10.1002/brb3.1016 · Cited by 29
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Mester, C. T., Wiste, H. J., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Reid, R. I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38878-8 · Cited by 29
Self-citationAutophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice
Wang, H.-C., Zhang, T., Kuerban, B., Jin, Y.-L., Le, W., Hara, H., Fan, D.-S., Wang, Y., Tabira, T., & Chui, D.-H. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1546-4 · Cited by 29
Feasibility and acceptance of simultaneous amyloid PET/MRI
Schütz, L., Lobsien, D., Fritzsch, D., Tiepolt, S., Werner, P., Schroeter, M. L., Berrouschot, J., Saur, D., Hesse, S., Jochimsen, T. H., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3462-x · Cited by 29
Alzheimer disease biomarkers and insights into mild cognitive impairment
Knopman, D. S. (2013) · Neurology · doi:10.1212/wnl.0b013e31828728ac · Cited by 28
Self-citationJang, H., Shin, D., Kim, Y., Kim, K. W., Lee, J., Kim, J. P., Kim, H. J., Cho, S. H., Kim, S. E., Na, D. L., et al. (2024) · Dementia and Neurocognitive Disorders · doi:10.12779/dnd.2024.23.4.212 · Cited by 29
Cerebrospinal Fluid Tau Levels Predict Prognosis in Non-Inherited Frontotemporal Dementia
Borroni, B., Benussi, A., Cosseddu, M., Archetti, S., & Padovani, A. (2013) · Neurodegenerative Diseases · doi:10.1159/000353280 · Cited by 28
Decreased hippocampal metabolism in high‐amyloid mild cognitive impairment
Hanseeuw, B. J., Schultz, A. P., Betensky, R. A., Sperling, R. A., & Johnson, K. A. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.2357 · Cited by 28
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., Roberts, R. O., Rocca, W. A., Boeve, B. F., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-04-09
- Volume
- 71
- Issue
- 6
- Pages
- 765-775
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3586223
- OpenAlex
- W2044429455
- Cited by
- 602
- References
- 71
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 21 · 2023: 28 · 2022: 29 · 2021: 40 · 2020: 33 · 2019: 40 · 2018: 44 · 2017: 60 · 2016: 80 · 2015: 65 · 2014: 63 · 2013: 51 · 2012: 10
- FWCI
- 27.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- National Institute on Aging (R01AG11378, P50‐AG16574, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
- National Center for Research Resources (C06RR018898)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- preclinical Alzheimer's disease, NIA-AA criteria, Pittsburgh compound B PET, cerebral amyloidosis, FDG-PET, hippocampal volume, neurodegeneration biomarkers, cognitively normal older adults, diagnostic classification
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Brain, Cognition Disorders, Female, Humans, Longitudinal Studies, Male, Mental Status Schedule, Neuropsychological Tests, Thiazoles, United States, Biomarkers, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
